Ratings Ondine Biomedical Inc.

Equities

Delayed London S.E. Other stock markets 04:33:00 2024-05-10 am EDT			5-day change	1st Jan Change
7.34 ^GBX	+4.86%		+11.21%	-16.11%

May. 08	Hellenic Dynamics and Ondine Biomedical raise funds	AN
May. 03	Ondine Biomedical shares rise on fundraise to advance Steriwave	AN

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	ESG Refinitiv
ONDINE BIOMEDICAL INC.	-16.11%	19.86M	-
ABBOTT LABORATORIES	-4.91%	182B	C+
MEDTRONIC PLC	+0.46%	110B	C
BECTON, DICKINSON AND COMPANY	-3.62%	67.92B	A
DEXCOM, INC.	+3.26%	50.96B	B-
CENCORA, INC.	+9.11%	44.7B	B-
HOYA CORPORATION	+2.70%	40.66B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+6.39%	27.6B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.83%	26.63B	A-
TERUMO CORPORATION	+13.67%	24.84B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality